Biblio

Martin LF, Cheng K, Washington SM, Denton M, Goel V, Khandekar M, Largent-Milnes TM, Patwardhan A, Ibrahim MM.  2023.  Green Light Exposure Elicits Anti-inflammation, Endogenous Opioid Release and Dampens Synaptic Potentiation to Relieve Post-surgical Pain.. J Pain. 24(3):509-529.

Doyle TM, Janes K, Chen Z, Grace PM, Esposito E, Cuzzocrea S, Largent-Milnes TM, Neumann WL, Watkins LR, Spiegel S et al..  2020.  Activation of sphingosine-1-phosphate receptor subtype 1 in the central nervous system contributes to morphine-induced hyperalgesia and antinociceptive tolerance in rodents.. Pain. 161(9):2107-2118.

Stine C, Coleman DL, Flohrschutz AT, Thompson AL, Mishra S, Blagg BS, Largent-Milnes TM, Lei W, Streicher JM.  2020.  Heat shock protein 90 inhibitors block the antinociceptive effects of opioids in mouse chemotherapy-induced neuropathy and cancer bone pain models.. Pain. 161(8):1798-1807.

Thompson AL, Largent-Milnes TM, Vanderah TW.  2019.  Animal Models for the Study of Bone-Derived Pain.. Methods Mol Biol. 1914:391-407.

Hay M, Polt R, Heien ML, Vanderah TW, Largent-Milnes TM, Rodgers K, Falk T, Bartlett MJ, Doyle KP, Konhilas JP.  2019.  A Novel Angiotensin-(1-7) Glycosylated Mas Receptor Agonist for Treating Vascular Cognitive Impairment and Inflammation-Related Memory Dysfunction.. J Pharmacol Exp Ther. 369(1):9-25.

Chen Z, Doyle TM, Luongo L, Largent-Milnes TM, Giancotti LAntonio, Kolar G, Squillace S, Boccella S, Walker JK, Pendleton A et al..  2019.  Sphingosine-1-phosphate receptor 1 activation in astrocytes contributes to neuropathic pain.. Proc Natl Acad Sci U S A. 116(21):10557-10562.

Pandit V, Khan M, Zakaria ERasheid, Largent-Milnes TM, Hamidi M, O'Keeffe T, Vanderah TW, Joseph B.  2018.  Continuous remote ischemic conditioning attenuates cognitive and motor deficits from moderate traumatic brain injury.. J Trauma Acute Care Surg. 85(1):48-53.

Ramos-Colon CN, Lee YSun, Remesic M, Hall SM, LaVigne J, Davis P, Sandweiss AJ, McIntosh MI, Hanson J, Largent-Milnes TM et al..  2016.  Structure-Activity Relationships of [des-Arg(7)]Dynorphin A Analogues at the κ Opioid Receptor.. J Med Chem. 59(22):10291-10298.

Deekonda S, Wugalter L, Kulkarni V, Rankin D, Largent-Milnes TM, Davis P, BassiriRad NM, Lai J, Vanderah TW, Porreca F et al..  2015.  Discovery of 5-substituted tetrahydronaphthalen-2yl-methyl with N-phenyl-N-(piperidin-4-yl)propionamide derivatives as potent opioid receptor ligands.. Bioorg Med Chem. 23(18):6185-94.

Giri AKumar, Apostol CR, Wang Y, Forte BL, Largent-Milnes TM, Davis P, Rankin D, Molnar G, Olson KM, Porreca F et al..  2015.  Discovery of Novel Multifunctional Ligands with μ/δ Opioid Agonist/Neurokinin-1 (NK1) Antagonist Activities for the Treatment of Pain.. J Med Chem. 58(21):8573-83.

Fawley JA, Hofmann ME, Largent-Milnes TM, Andresen MC.  2015.  Temperature differentially facilitates spontaneous but not evoked glutamate release from cranial visceral primary afferents.. PLoS One. 10(5):e0127764.

Hegarty DM, Hermes SM, Largent-Milnes TM, Aicher SA.  2014.  Capsaicin-responsive corneal afferents do not contain TRPV1 at their central terminals in trigeminal nucleus caudalis in rats.. J Chem Neuroanat. 61-62:1-12.

Hofmann ME, Largent-Milnes TM, Fawley JA, Andresen MC.  2014.  External QX-314 inhibits evoked cranial primary afferent synaptic transmission independent of TRPV1.. J Neurophysiol. 112(11):2697-706.

Largent-Milnes TM, Hegarty DM, Aicher SA, Andresen MC.  2014.  Physiological temperatures drive glutamate release onto trigeminal superficial dorsal horn neurons.. J Neurophysiol. 111(11):2222-31.

Tumati S, Largent-Milnes TM, Keresztes A, Ren J, Roeske WR, Vanderah TW, Varga EV.  2012.  Repeated morphine treatment-mediated hyperalgesia, allodynia and spinal glial activation are blocked by co-administration of a selective cannabinoid receptor type-2 agonist.. J Neuroimmunol. 244(1-2):23-31.

Tumati S, Largent-Milnes TM, Keresztes AI, Yamamoto T, Vanderah TW, Roeske WR, Hruby VJ, Varga EV.  2012.  Tachykinin NK₁ receptor antagonist co-administration attenuates opioid withdrawal-mediated spinal microglia and astrocyte activation.. Eur J Pharmacol. 684(1-3):64-70.

Yamamoto T, Nair P, Largent-Milnes TM, Jacobsen NE, Davis P, Ma S-W, Yamamura HI, Vanderah TW, Porreca F, Lai J et al..  2011.  Discovery of a potent and efficacious peptide derivative for δ/μ opioid agonist/neurokinin 1 antagonist activity with a 2',6'-dimethyl-L-tyrosine: in vitro, in vivo, and NMR-based structural studies.. J Med Chem. 54(7):2029-38.

Hanlon KE, Herman DS, Agnes RS, Largent-Milnes TM, Kumarasinghe IR, Ma SW, Guo W, Lee Y-S, Ossipov MH, Hruby VJ et al..  2011.  Novel peptide ligands with dual acting pharmacophores designed for the pathophysiology of neuropathic pain.. Brain Res. 1395:1-11.

Lozano-Ondoua AN, Wright C, Vardanyan A, King T, Largent-Milnes TM, Nelson M, Jimenez-Andrade JMiguel, Mantyh PW, Vanderah TW.  2010.  A cannabinoid 2 receptor agonist attenuates bone cancer-induced pain and bone loss.. Life Sci. 86(17-18):646-53.

Largent-Milnes TM, Guo W, Wang H-Y, Burns LH, Vanderah TW.  2008.  Oxycodone plus ultra-low-dose naltrexone attenuates neuropathic pain and associated mu-opioid receptor-Gs coupling.. J Pain. 9(8):700-13.